Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DRH80V
|
|||
| Drug Name |
JNJ-53718678
|
|||
| Synonyms |
Rilematovir; JNJ-678; UNII-NQ99E8OH3P; NQ99E8OH3P; 1383450-81-4; 3-((5-chloro-1-(3-(methylsulfonyl)propyl)-1H-indol-2-yl)methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one; 3-[[5-Chloranyl-1-(3-Methylsulfonylpropyl)indol-2-Yl]methyl]-1-[2,2,2-Tris(Fluoranyl)ethyl]imidazo[4,5-C]pyridin-2-One; Rilematovir [INN]; CHEMBL4437054; SCHEMBL17529353; HY-112180; CS-0043622; C(CCN1C(=CC2=CC(=CC=C12)Cl)CN1C2=C(N(C1=O)CC(F)(F)F)C=CN=C2)S(=O)(=O)C; 2H-Imidazo(4,5-C)pyridin-2-one, 3-((5-chloro-1-(3-(methylsulfonyl)propyl)-1H-indol-2-yl)methyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-; 3-((5-Chloro-1-(3-methylsulfonylpropyl)indol-2-yl)methyl)-1-(2,2,2-trifluoroethyl)imidazo(4,5-C)pyridin-2-one; 6YA
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Respiratory syncytial virus infection [ICD-11: 1C80; ICD-9: 79.6] | Phase 2 | [1] | |
| Company |
Janssen
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H20ClF3N4O3S
|
|||
| Canonical SMILES |
CS(=O)(=O)CCCN1C2=C(C=C(C=C2)Cl)C=C1CN3C4=C(C=CN=C4)N(C3=O)CC(F)(F)F
|
|||
| InChI |
1S/C21H20ClF3N4O3S/c1-33(31,32)8-2-7-27-16(10-14-9-15(22)3-4-17(14)27)12-28-19-11-26-6-5-18(19)29(20(28)30)13-21(23,24)25/h3-6,9-11H,2,7-8,12-13H2,1H3
|
|||
| InChIKey |
GTQTUABHRCWVLL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1383450-81-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Respiratory syncytial virus protein F (RSV F) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04056611) Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV) (FREESIA). U.S. National Institutes of Health. | |||
| REF 2 | Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study. J Infect Dis. 2018 Jul 24;218(5):748-756. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.